<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dimercaprol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dimercaprol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dimercaprol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9367" href="/d/html/9367.html" rel="external">see "Dimercaprol: Drug information"</a> and <a class="drug drug_patient" data-topicid="15552" href="/d/html/15552.html" rel="external">see "Dimercaprol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F160824"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bal in Oil [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866613"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bal in Oil [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057939"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Arsenic Toxicity</span>;</li>
<li>
<span class="list-set-name">Antidote, Gold Toxicity</span>;</li>
<li>
<span class="list-set-name">Antidote, Lead Toxicity</span>;</li>
<li>
<span class="list-set-name">Antidote, Mercury Toxicity</span>;</li>
<li>
<span class="list-set-name">Chelating Agent, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F160833"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended. Premedication with a histamine H<sub>1</sub> antagonist (eg, diphenhydramine) is recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bebbffe-d8e4-488d-813d-92185c987fad">Arsenic or gold poisoning, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arsenic or gold poisoning, acute: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild symptoms: </i> Infants, Children, and Adolescents: IM: 2.5 mg/kg/dose every 6 hours for 2 days, then every 12 hours on the third day, and once daily thereafter for 10 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe symptoms</i>: Infants, Children, and Adolescents: IM: 3 mg/kg/dose every 4 hours for 2 days then every 6 hours on the third day, then every 12 hours thereafter for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2256856c-893e-468b-a3cd-0ec3b6b173a2">Lead poisoning, adjunct with edetate CALCIUM disodium</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning, adjunct with edetate CALCIUM disodium:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For the treatment of high blood lead levels (BLL) in children, the CDC recommends chelation treatment when BLL &gt;45 mcg/dL (ACCLPP 2012; CDC 2002); however, dimercaprol is only recommended for use (in combination with edetate CALCIUM disodium) in children whose BLL ≥70 mcg/dL or in pediatric patients with lead encephalopathy (AAP 2005; AAP [Shenoi 2020]; Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptomatic (without encephalopathy) or BLL ≥70 mcg/dL</i>: IM: 3 to 4 mg/kg/dose (50 to 75 mg/<b>m<sup>2</sup></b>/dose) every 4 hours for 3 to 5 days in combination with edetate CALCIUM disodium; dose and duration should be based on symptoms and blood lead levels. <b>Note:</b> Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose (AAP [Shenoi 2020]; Calello 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Encephalopathy:</i> IM: 4 mg/kg/dose (75 mg/<b>m<sup>2</sup></b>/dose) every 4 hours for 5 days in conjunction with edetate CALCIUM disodium; dose and duration should be based on symptoms and blood lead levels; <b>Note:</b> Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose (AAP [Shenoi 2020]; Calello 2018).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Treatment courses may be repeated; at least 2 days should lapse before retreatment (Calello 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5db0132-86a1-412f-94c3-fb941dd1e8ae">Mercury poisoning, elemental or inorganic; acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mercury poisoning, elemental or inorganic; acute:</b> Infants, Children, and Adolescents: IM: 5 mg/kg initially followed by 2.5 mg/kg/dose 1 to 2 times/day for 10 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109274"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no adjustments provided in manufacturer's labeling. Use with extreme caution or discontinue if acute renal insufficiency develops during therapy. <b>Note</b>: Extracorporeal elimination in patients with preexisting renal disease may enhance the removal of the chelator-metal complex (Hsiao 2019).</p></div>
<div class="block dohp drugH1Div" id="F51109275"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in hepatic insufficiency (except in cases of postarsenical jaundice).</p></div>
<div class="block doa drugH1Div" id="F160826"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9367" href="/d/html/9367.html" rel="external">see "Dimercaprol: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended. Premedication with a histamine H<sub>1</sub> antagonist (eg, diphenhydramine) is recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1bebbffe-d8e4-488d-813d-92185c987fad">Arsenic or gold poisoning, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arsenic or gold poisoning, acute:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild symptoms:</i>
<b>IM:</b> 2.5 mg/kg every 6 hours for 2 days, then every 12 hours for 1 day, followed by once daily for 10 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe symptoms:</i>
<b>IM:</b> 3 mg/kg every 4 hours for 2 days, then every 6 hours for 1 day, followed every 12 hours for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad6c1520-f76f-4866-9ee2-58ecc5033ef3">Lead poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning:</b>
<b>Note:</b> Available guidelines recommend chelation therapy with blood lead levels (BLL) &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated for most patients with BLL &gt;80 mcg/dL and all patients with BLL ≥100 mcg/dL and/or symptoms (CSTE 2013; Kosnett 2007). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptoms suggestive of encephalopathy or BLL &gt;100 mcg/dL:</i>
<b>IM: </b>3 to 4 mg/kg (50 to 75 mg/m<sup>2</sup>) every 4 hours for 3 to 5 days in conjunction with edetate CALCIUM disodium; dose and duration should be based on symptoms and BLL. <b>Note: </b>Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Encephalopathy: </i>
<b>IM: </b>4 mg/kg (75 mg/m<sup>2</sup>) every 4 hours for 5 days in conjunction with edetate CALCIUM disodium. <b>Note: </b>Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose (Calello 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment courses may be repeated, but 2-week intervals between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment. High initial BLL (eg, &gt;100 mcg/dL) or presence of lead encephalopathy may indicate the need for more prompt re-treatment (Calello 2018); consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning is highly recommended.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a80997dd-a6ec-4fa3-826b-1cc7300bdc3e">Lewisite exposure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lewisite exposure (off-label use):</b>
<b>IM:</b> 3 to 5 mg/kg/dose every 4 hours for 4 doses; adjustments can be made depending upon severity of exposure (ATSDR 2021).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="745f981d-63bd-4448-8fe4-3e244201a0b7">Mercury poisoning, inorganic, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mercury poisoning, inorganic, acute:</b>
<b>IM:</b> 5 mg/kg initially, followed by 2.5 mg/kg 1 to 2 times/day for 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="050653d6-bc4d-4cf8-be70-4a692db114a9">Polonium internal contamination</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polonium (Po-210) internal contamination (off-label use):</b>
<b>IM:</b> 2.5 mg/kg/dose 4 times daily for 2 days, then twice daily on day 3, then once daily on days 4 through 10 for a total treatment duration of 10 days (Jefferson 2009; REMM 2021).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991322"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling. Use with extreme caution or discontinue if acute renal insufficiency develops during therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Extracorporeal elimination in patients with preexisting renal disease may enhance the removal of the chelator-metal complex (Hsiao 2019).</p></div>
<div class="block doha drugH1Div" id="F50988666"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated in hepatic insufficiency (except in cases of postarsenical jaundice). </p></div>
<div class="block adr drugH1Div" id="F160803"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Chest pain, hypertension (dose-related), tachycardia (dose-related)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Anxiety, burning sensation (lips, mouth, throat), headache, nervousness, paresthesia (hand)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, nausea, salivation, sore throat, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Burning sensation of the penis</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Leukopenia (polymorphonuclear)</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Abscess</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blepharospasm, conjunctivitis, lacrimation</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Renal insufficiency (acute)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pharyngeal edema, rhinorrhea, throat irritation</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever (children ~30%)</p></div>
<div class="block coi drugH1Div" id="F160816"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hepatic insufficiency (unless due to arsenic poisoning).</p></div>
<div class="block war drugH1Div" id="F160800"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Potentially a nephrotoxic drug; use with caution in patients with oliguria. Maintain an alkaline urine pH to protect the kidneys (prevents dimercaprol-metal complex breakdown). Discontinue or use with extreme caution if renal insufficiency develops during treatment. Hemodialysis may be used to remove the dimercaprol-metal chelate in patients with renal dysfunction</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency; may increase the risk of hemolytic anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Fever may occur in ~30% of children and may persist for the duration of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to re-enter the contaminated environment until lead abatement has been completed. Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended before initiating chelation therapy. The poison control center or local health department should be contacted for assistance with patient and family support as well as lead abatement.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peanut oil: Product contains peanut oil; use with caution in patients with peanut allergy; medication for the treatment of hypersensitivity reactions should be available for immediate use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Administer all injections deep IM at different sites; <b>not</b> for IV administration. May cause significant pain upon injection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for the treatment of iron, cadmium, or selenium poisoning; use in these patients may result in the production of a toxic dimercaprol-metal complex.</p></div>
<div class="block foc drugH1Div" id="F160810"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bal in Oil: 100 mg/mL (3 mL [DSC]) [contains benzyl benzoate, peanut oil]</p></div>
<div class="block geq drugH1Div" id="F160796"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866614"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL ([DSC])</p></div>
<div class="block admp drugH1Div" id="F52612578"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer undiluted, <b>deep</b> IM; rotate injection sites; prior to administration, consider injection site anesthetic (eg, lidocaine infiltration or topical lidocaine [or with prilocaine]) (AAP [Shenoi 2020]). Keep urine alkaline to protect renal function. When used in the treatment of lead poisoning, administer in a separate site from edetate CALCIUM disodium.</p></div>
<div class="block adm drugH1Div" id="F160813"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer all injections by deep IM injection.  Rotate injection sites. Maintain an alkaline urine pH to protect renal function. When used in the treatment of lead poisoning, administer in a separate site from edetate CALCIUM disodium.</p></div>
<div class="block sts drugH1Div" id="F3072405"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes: </i>Guidelines suggest that at least 2.4 g of dimercaprol be stocked, especially in hospitals in industrial areas or where there is a prevalence of heavy metal risk factors. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53566531"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of gold, arsenic (except arsine), or acute elemental or inorganic mercury poisoning (except organic mercury compounds); adjunct prior to edetate CALCIUM disodium in acute lead poisoning (All indications: FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> There may be more effective and less toxic alternatives to dimercaprol; consultation with a poison control center or an expert in the treatment of heavy metal poisoning is highly recommended. The use of dimercaprol in the management of poisoning from other heavy metals has not been validated.</p></div>
<div class="block cyt drugH1Div" id="F13299205"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F160804"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Dimercaprol may enhance the nephrotoxic effect of Iron Preparations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Dimercaprol may enhance the adverse/toxic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, Dimercaprol may enhance the nephrotoxic effect of Iron Salts. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F5026033"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.</p>
<p style="text-indent:0em;margin-top:2em;">Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels. Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment. Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL. In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels ≥45 mcg/dL (pregnant women with blood lead levels ≥70 mcg/dL should be considered for chelation regardless of trimester). There are alternatives to the use of dimercaprol and consultation with experts in lead poisoning and high-risk pregnancy is recommended. Encephalopathic pregnant women should be chelated regardless of trimester (CDC 2010).</p></div>
<div class="block mopp drugH1Div" id="F53566485"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function, urine pH, infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Arsenic poisoning:</b> Urine arsenic concentration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning:</b> Blood lead levels (baseline and 7 to 21 days after completing chelation therapy); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin, or zinc protoporphyrin; neurodevelopmental changes.</p></div>
<div class="block pha drugH1Div" id="F160799"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The sulfhydryl group of dimercaprol combines with ions of various heavy metals to form relatively stable, nontoxic, soluble chelates which are excreted in urine.</p></div>
<div class="block phk drugH1Div" id="F160815"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Rapid; Oral: Not absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: To all tissues including the brain.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; rapid to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 0.5 to 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces via bile.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038601"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sulfactin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">B.a.l.</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">B a l</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">B a l</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bal | Bal afp</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sulfactin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sulfactin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">B.a.l.</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">B.a.l. | Sulfactin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dimercarpol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">B a l</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATSDR.1">
<a name="ATSDR.1"></a>Agency for Toxic Substances and Disease Registry (ATSDR). Blister Agents: Lewisite (L) (C 2 2 3 H AsCl ) CAS 541-25-3, UN 1556; and Mustard-Lewisite Mixture (HL) CAS Number not available, UN 2810. In: Managing Hazardous Materials Incidents. <a href="https://www.atsdr.cdc.gov/MHMI/mmg163.pdf" target="_blank">https://www.atsdr.cdc.gov/MHMI/mmg163.pdf</a>. Accessed November 11, 2021.</div>
</li>
<li>
<div class="reference">
                  BAL in Oil (dimercaprol) [prescribing information]. Gurnee, IL: Akorn Operating Company LLC; May 2022.</div>
</li>
<li>
<div class="reference">
                  Calello DP, Henretig FM. Lead. In: <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. McGraw Hill Inc; 2018;1292-1308.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6285552">
<a name="6285552"></a>Cantilena LR Jr, Klaassen CD. The Effect of Chelating Agents on the Excretion of Endogenous Metals. <i>Toxicol Appl Pharmacol</i>. 1982;63(3):344-350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/6285552/pubmed" id="6285552" target="_blank">6285552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevetion (CDC). <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>. CDC; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975528">
<a name="17975528"></a>Centers for Disease Control and Prevention (CDC). Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention. <i>MMWR Recomm Rep</i>. 2007;56(RR-8):1-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/17975528/pubmed" id="17975528" target="_blank">17975528</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>. CDC; 2002.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Low level lead exposure harms children. A renewed call for primary prevention. 2012. <a href="https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf" target="_blank">https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf</a>
</div>
</li>
<li>
<div class="reference">
                  Council of State and Territorial Epidemiologists (CSTE). Management guidelines for blood lead levels in adults. <a href="https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf" target="_blank">https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf</a>. Published June 12, 2013. Accessed January 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11285436">
<a name="11285436"></a>Gardella C. Lead Exposure in Pregnancy: A Review of the Literature and Argument for Routine Prenatal Screening. <i>Obstet Gynecol Surv</i>. 2001;56(4):231-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/11285436/pubmed" id="11285436" target="_blank">11285436</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hazardous Substances Data Bank (HSDB). Dimercaprol. Bethesda (MD): National Library of Medicine (US). Last revised September 2010. http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@DOCNO+4004</div>
</li>
<li>
<div class="reference">
                  Howland MA. Antidotes in Depth: Succimer (2,3-dimercaptosuccinic acid) and DMPS (2,3-dimercapto-1-propanesulfonic acid). In: <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. McGraw Hill Inc; 2018;1309-1314.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31623560">
<a name="31623560"></a>Hsiao CY, Gresham C, Marshall MR. Treatment of lead and arsenic poisoning in anuric patients - a case report and narrative review of the literature. <i>BMC Nephrol</i>. 2019;20(1):374. doi:10.1186/s12882-019-1561-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/31623560/pubmed" id="31623560" target="_blank">31623560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19492929">
<a name="19492929"></a>Jefferson RD, Goans RE, Blain PG, Thomas SH. Diagnosis and treatment of polonium poisoning. <i>Clin Toxicol (Phila)</i>. 2009;47(5):379-392. doi:10.1080/15563650902956431<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/19492929/pubmed" id="19492929" target="_blank">19492929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20664538">
<a name="20664538"></a>Kosnett MJ. Chelation for Heavy Metals (Arsenic, Lead, and Mercury): Protective or Perilous? <i>Clin Pharmacol Ther</i>. 2010;88(3):412-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/20664538/pubmed" id="20664538" target="_blank">20664538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1331492">
<a name="1331492"></a>Kosnett MJ. Unanswered Questions in Metal Chelation. <i>J Toxicol Clin Toxicol</i>. 1992;30(4):529-547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/1331492/pubmed" id="1331492" target="_blank">1331492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17431500">
<a name="17431500"></a>Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for Medical Management of Adult Lead Exposure. <i>Environ Health Perspect</i>. 2007;115(3):463-471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/17431500/pubmed" id="17431500" target="_blank">17431500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199720">
<a name="16199720"></a>Lead Exposure in Children: Prevention, Detection, and Management. American Academy of Pediatrics Committee on Environmental Health. <i>Pediatrics</i>. 2005;116(4):1036-1046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/16199720/pubmed" id="16199720" target="_blank">16199720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24616453">
<a name="24616453"></a>Schnur J, John RM. Childhood lead poisoning and the new Centers for Disease Control and Prevention guidelines for lead exposure. <i>J Am Assoc Nurs Practitioners</i>. 2014;26(5):238-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/24616453/pubmed" id="24616453" target="_blank">24616453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12540252">
<a name="12540252"></a>Shannon M. Severe Lead Poisoning in Pregnancy. <i>Ambul Pediatr</i>. 2003;3(1):37-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/12540252/pubmed" id="12540252" target="_blank">12540252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaprol-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-REMM.1">
<a name="REMM.1"></a>US Department of Health and Human Services Radiation Emergency Medical Management (REMM). Managing Internal Radiation Contamination. <a href="https://remm.hhs.gov/int_contamination.htm#blockingagents_2" target="_blank">https://remm.hhs.gov/int_contamination.htm#blockingagents_2</a>. Accessed September 23, 2021.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 13235 Version 116.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
